Preview

Russian Journal of Child Neurology

Advanced search

POSSIBILITIES FOR ANTIEPILEPTIC DRUGS USE IN THE TREATMENT OF TIC HYPERKINESIS AND TOURETTE SYNDROME IN CHILDREN

https://doi.org/10.17650/2073-8803-2016-11-4-20-26

Abstract

Objective: to evaluate the efficacy of topiramate at a dose of 1–2 mg/kg in 34 patients aged 7–17 with tic hyperkinesis and Tourette syndrome (TS).

Materials and methods. We performed clinical evaluation of hyperkinesis severity along with the assessment of somatosensory evoked potentials (SSEP) and the analysis of surface electromyography (EMG) data prior to treatment initiation and after 6 weeks of therapy. SSEP investigation was carried out in accordance with a standard protocol. Interpeak latencies on the tracks Cp–Fpz (D, S), Cerv6–Fpz (D, S), Erb’i–Erb’c (D, S) were evaluated in order to determine the afferentation between relevant brain structures: N9–N13, N13–N20, N9–N20. N20–P23 potentials reflected primary activity of somatosensory cortex. The investigation of tic hyperkinesis was conducted using surface EMG of facial muscles (m. orbicularis oculi), the muscles of the shoulder girdle (m. supraspinatus), and the muscles of the upper extremities (m. flexor digitorum superficialis) according to the standard protocol. Interference curve was recorded at rest and after hyperkinesis stimulation with the use of provocative tests. High-amplitude (more than 500 mkV) oscillations were considered as burst activity. The severity of clinical manifestations was evaluated using the Yale Global Tic Severity Scale (1989) and the method of tics counting during 20 minutes (V.P. Zykov, 2009). The control group comprised 15 healthy children matched for sex and age.

Results. The use of topiramate in patients with chronic motor/vocal tics and TS has significantly decreased the severity of hyperkinesis manifestations, evaluated both by the Yale Global Tic Severity Scale (p < 0,05) and by the method of tics counting during 20 minutes (p < 0,05). It also helped to decrease the prevalence of burst activity in EMG while registering hyperkinesis in different muscle groups. SSEP data showed the normalization of interpeak latency values and the decrease of N20–P23 potentials amplitude, which reflects the decline in the activity of brain somatosensory system, represented by thalamo-cortical structures.

Conclusion. Surface EMG and SSEP methods can be used for evaluation of treatment efficacy in cases of tic hyperkinesis and TS.

About the Authors

V. P. Zykov
Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia
Russian Federation
2/1 Barrikadnaya St., Moscow 125995


E. A. Kashirina
Children’s City Polyclinic No 110
Russian Federation
39 Dekabristov St., Moscow 127490


Yu. V. Naugol’nykh
Children’s City Polyclinic No 110
Russian Federation
39 Dekabristov St., Moscow 127490


References

1. Антонов И.П., Шанько Г.Г. Гиперкинезы у детей: вопросы этиологии, патогенеза, лечения. Минск: Наука и техника, 1975. 213 с. [Antonov I.P., Shan’ko G.G. Hyperkinesis in children: etiology, pathogenesis, treatment. Minsk: Nauka i tekhnika, 1975. 213 p. (In Russ.)].

2. Боголепов Н.К. Экстрапирамидная система. В кн.: Большая медицинская энциклопедия. Т. 35. М.: Советская энциклопедия, 1964. С. 25. [Bogolepov N.K. Extrapyramidal system. In: Big medical encyclopedia. V. 35. Moscow: Sovetskaya entsiklopediya, 1964. P. 25. (In Russ.)].

3. Гнездицкий В.В., Корепина О.С. Атлас по вызванным потенциалам мозга. Иваново: ПрессСто, 2011. 532 с. [Gnezditskiy V.V., Korepina O.S. Atlas of brain induced potentials. Ivanovo: PressSto, 2011. 532 p. (In Russ.)].

4. Зенков Л.Р., Ронкин М.А. Функциональная диагностика нервных заболеваний. M.: МЕДпресс-информ, 2011. 488 с. [Zenkov L.R., Ronkin M.A. Functional diagnostics of neurological diseases. Moscow: MEDpress-inform, 2011. 488 p. (In Russ.)].

5. Зыков В.П., Мосин И.М., Сафронов Д.Л. Зрительные вызванные потенциалы у больных эпилепсией в раннем возрасте. Эпилепсия и пароксизмальные состояния 2009;1(1):14–20. [Zykov V.P., Mosin I.M., Safronov D.L. Visual evoked potentials in infants with epilepsy. Epilepsiya i paroksizmal’nye sostoyaniya = Epilepsy and Paroxysmal States 2009;1(1):14–20. (In Russ.)].

6. Зыков В.П. Клиническая синдромология, патогенез, комплексная терапия тиков у детей. Автореф. дис. … д-ра мед. наук. М., 1999. 38 с. [Zykov V.P. Clinical syndromology, pathogenesis, complex therapy of tics in children. Author’s abstract of thesis … of doctor of medical sciences. Moscow, 1999. 38 p. (In Russ.)].

7. Зыков В.П. Тики детского возраста. М.: МБН, 2002. 163 с. [Zykov V.P. Tics in childhood. Moscow: MBN, 2002. 163 p. (In Russ.)].

8. Зыков В.П. Эволюция синдрома Туретта. В сб.: Аннотированные доклады по материалам II Национального конгресса по болезни Паркинсона и расстройствам движений. М., 2011. С. 247–50. [Zykov V.P. The evolution of Tourette’s syndrome. In: Annotated reports based on the materials of the II National Congress of Parkinson’s disease and movement disorders. Moscow, 2011. Pp. 247–50. (In Russ.)].

9. Левин О.С. Тикозные гиперкинезы. В кн.: Экстрапирамидные расстройства: руководство по лечению и диагностике. Под ред. В.Н. Штока, И.А. Ивановой-Смоленской. М., 2002. С. 313–25, 327–55. [Levin O.S. Tic hyperkinesis. In: Extrapyramidal disorders: a guide for treatment and diagnosis. Ed. by V.N. Shtok, I.A. Ivanova-Smolenskaya. Moscow, 2002. Pp. 313–25, 327–55. (In Russ.)].

10. Шанько Г.Г. Генерализованный тик (болезнь Жиль де ля Туретта) у детей и подростков: методические рекомендации. Минск: Наука и техника, 1990. 29 с. [Shan’ko G.G. Generalized tic disorder (Gilles de la Tourette’s disease) in children and adolescents: guidelines. Minsk: Nauka i tekhnika, 1990. 29 p. (In Russ.)].

11. Bamard E.A., Skolnick P., Olsen R.W. et al. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acid A receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998;50(2):291–313.

12. Chen Y.C., Kung S.S., Chen B.Y. et al. Identifications, classification, and evolution of the vertebrate alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor subunit genes. J Mol Evol 2001;53(6):690–702.

13. Costa E. From GABAA receptor diversity emerges a unified vision of GABA-ergic inhibition. Annu Rev Pharmacol Toxicol 1998:38:321–50.

14. Freeman R.D., Fask D.K., Burd L. et al. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Med Child Neurol 2000;42:436–47.

15. Jankovich J. Tourette’s disorder. N Eng J Med 2001;16(345):15–29.

16. Leckman J.F., Riddle M.A., Hardin M.T. et al. The Yale Global Tic Severity Scale; initial testing of a clinical-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989:28:566–73.

17. Mills S., Heddrly T. A giude to childhood motor stereotypes, tic disorders and the Tourette spectrum for the primary care practitioner. Ulster Med J 2014:83(1):22–30.

18. Yang C.S., Zhang L.N., Zeng L.N. et al. Topiramate for Tourette’s syndrome in children a meta-analysis. Pediatr Neurol 2013;49(5).


Review

For citations:


Zykov V.P., Kashirina E.A., Naugol’nykh Yu.V. POSSIBILITIES FOR ANTIEPILEPTIC DRUGS USE IN THE TREATMENT OF TIC HYPERKINESIS AND TOURETTE SYNDROME IN CHILDREN. Russian Journal of Child Neurology. 2016;11(4):20-26. (In Russ.) https://doi.org/10.17650/2073-8803-2016-11-4-20-26

Views: 1875


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2073-8803 (Print)
ISSN 2412-9178 (Online)